← All Stocks

Danaher Corporation

DHR · NYQ
$221.56+21.26%
52W Low: $160.9352W High: $242.80
Current: $221.56  ·  74% of 52-week range
HealthcareDiagnostics & ResearchNYQ
View live charts, options flow & technicals for Danaher Corporation → Open Dashboard

Danaher Corporation (DHR) is a healthcare company in the diagnostics & research industry with $25.11B in trailing revenue trading at a 39.4× trailing P/E — analyst consensus: strong buy.

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.

Key Statistics

Market Cap$155.75B
Revenue (TTM)$25.11B
EPS (TTM)$5.63
EPS (Fwd est.)$9.30
Employees58,000
Trailing P/E39.35
Forward P/E23.83
PEG Ratio1.32
Price / Sales6.20
Price / Book2.96
EV / EBITDA22.33
Beta (5Y)0.81

Analyst Consensus

Consensus
Strong Buy
Analyst Price Target
+4.2% upside
Target: $230.83

Annual Revenue & Net Income

RevenueNet Income
'22
$26.64B
$7.21B
'23
$23.89B
$4.76B
'24
$23.88B
$3.90B
'25
$24.57B
$3.61B

Earnings History


QuarterActual EPSEstimateResult
Jul 2026
$1.94
$1.84Beat (+5.3%)
Apr 2026
$2.06
$1.94Beat (+6.5%)
Jan 2026
$2.23
$2.19Beat (+2.0%)
Oct 2025
$1.89
$1.72Beat (+9.8%)

Next Earnings Report

Danaher Corporation is next expected to report earnings on 21 Oct 2026.

Profitability

58.8%
19.8%
15.9%
Gross
Margin
Operating
Margin
Net
Margin
Revenue Growth (YoY)5.5%
Return on Equity7.6%
Return on Assets3.9%

Balance Sheet

Cash & Equivalents$4.35B
Total Debt$27.86B
Net Position$23.51B (net debt)
Free Cash Flow (TTM)$4.33B
Debt / Equity52.97

Share Ownership

Institutions 84.4%
Insiders 11.0%
Public 4.6%

Dividend

Annual Rate
$1.60
Yield
0.72%
Payout Ratio
25.7%
Ex-Dividend Date
30 Sep 2026
5Y Avg Yield
0.46%

Related Stocks

LLYUNHJNJMRKABBVTMOPFEISRG

Frequently Asked Questions

What does Danaher Corporation (DHR) do?
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the developmen…
What is DHR's market cap?
Danaher Corporation has a market capitalization of approximately $155.75B.
What is DHR's P/E ratio?
Danaher Corporation trades at a trailing P/E ratio of 39.4x and a forward P/E of 23.8x, which is above the broad market average of ~25x.
How much revenue does DHR generate?
Danaher Corporation generated $25.11B in trailing 12-month revenue.
What do analysts say about DHR?
The analyst consensus rating for Danaher Corporation is strong buy, with a mean price target of $230.83. That implies +4.2% upside from the current price.
When does DHR report earnings?
Danaher Corporation is next scheduled to report earnings on 21 Oct 2026.
Does DHR pay a dividend?
Yes. Danaher Corporation pays a dividend with a current yield of 0.72%, at an annual rate of $1.60 per share.

View live charts, options flow, gamma exposure, earnings history, and technical analysis for Danaher Corporation on Apsis Markets.

Open Live Dashboard →